IEA yields 14.58% · JNJ yields 2.13%● Live data
📍 IEA pulled ahead of the other in Year 1
Combined, IEA + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IEA + JNJ for your $10,000?
Infrastructure and Energy Alternatives, Inc., through its subsidiaries, operates as a diversified infrastructure construction company in the United States. The company engages in providing engineering, procurement, and construction (EPC) services for the renewable energy, traditional power, and civil infrastructure industries. It operates in two segments, Renewables and Specialty Civil. The Renewables segment provides a range of services, including full EPC project delivery, design, site development, construction, installation, and maintenance of infrastructure services for the wind and solar industries. The Specialty Civil segment offers a range of services that comprise environmental remediation services, such as site development, environmental site closure, and outsourced contract mining and coal ash management services; rail infrastructure services, including planning, design, procurement, construction, and maintenance of infrastructure projects for railway and intermodal facilities; and heavy civil construction services consisting of road and bridge construction, specialty paving, and industrial maintenance, as well as other local, state, and government projects. The company was founded in 1947 and is headquartered in Indianapolis, Indiana. As of October 7, 2022, Infrastructure and Energy Alternatives, Inc. operates as a subsidiary of MasTec, Inc..
Full IEA Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.